ECSP066717A - Compuestos de quinolina sustituidos - Google Patents
Compuestos de quinolina sustituidosInfo
- Publication number
- ECSP066717A ECSP066717A EC2006006717A ECSP066717A ECSP066717A EC SP066717 A ECSP066717 A EC SP066717A EC 2006006717 A EC2006006717 A EC 2006006717A EC SP066717 A ECSP066717 A EC SP066717A EC SP066717 A ECSP066717 A EC SP066717A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- substituted quinoline
- quinoline compounds
- compositions
- mtp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Esta invención se refiere a inhibidores de la secreción de MTP/Apo-B de Fórmula I (consta gráfico) donde R1-R7, X1, m y n son como se han definido en la memoria descriptiva así como a composiciones farmacéuticas que comprenden los compuestos, y a procedimientos de uso de los compuestos y composiciones. Los compuestos de la invención son útiles en el tratamiento de la obesidad y enfermedades, afecciones o trastornos asociados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54167804P | 2004-02-04 | 2004-02-04 | |
US63376304P | 2004-12-06 | 2004-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066717A true ECSP066717A (es) | 2006-10-31 |
Family
ID=34890449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006717A ECSP066717A (es) | 2004-02-04 | 2006-07-21 | Compuestos de quinolina sustituidos |
Country Status (25)
Country | Link |
---|---|
US (3) | US7468378B2 (es) |
EP (1) | EP1716137A1 (es) |
JP (1) | JP2007520543A (es) |
KR (1) | KR100799802B1 (es) |
AP (1) | AP2006003685A0 (es) |
AR (1) | AR047529A1 (es) |
AU (1) | AU2005214159A1 (es) |
BR (1) | BRPI0507462A (es) |
CA (1) | CA2555133A1 (es) |
CO (1) | CO5700721A2 (es) |
CR (1) | CR8544A (es) |
EA (1) | EA010369B1 (es) |
EC (1) | ECSP066717A (es) |
GE (1) | GEP20084360B (es) |
IL (2) | IL176715A0 (es) |
MA (1) | MA28347A1 (es) |
NL (1) | NL1028192C2 (es) |
NO (1) | NO20063928L (es) |
OA (1) | OA13365A (es) |
PA (1) | PA8623001A1 (es) |
PE (1) | PE20050773A1 (es) |
SV (1) | SV2007002007A (es) |
TW (2) | TWI306454B (es) |
UY (1) | UY28734A1 (es) |
WO (1) | WO2005080373A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
EA010369B1 (ru) * | 2004-02-04 | 2008-08-29 | Пфайзер Продактс Инк. | Замещенные хинолиновые соединения |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
JP2007532638A (ja) * | 2004-04-14 | 2007-11-15 | アストラゼネカ・アクチエボラーグ | Nk1アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用 |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
EP1877369B1 (en) | 2005-04-19 | 2013-07-10 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
CA2666539A1 (en) * | 2006-10-23 | 2008-05-02 | Pfizer Inc. | Substituted phenylmethyl bicyclocarboxyamide compounds |
EP2084127A1 (en) | 2006-11-13 | 2009-08-05 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
EP2115368A1 (en) * | 2007-02-02 | 2009-11-11 | Steve D. Shivvers | High efficiency drier with multi stage heating and drying zones |
US20080249130A1 (en) * | 2007-02-09 | 2008-10-09 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
WO2009014674A1 (en) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors |
ES2748136T3 (es) | 2007-10-15 | 2020-03-13 | United Animal Health Inc | Método para aumentar el rendimiento de las crías |
CA2702984C (en) | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
WO2010018547A1 (en) * | 2008-08-13 | 2010-02-18 | Pfizer Inc. | Aminoquinoline compounds |
WO2012177896A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
AP2013007331A0 (en) | 2011-06-24 | 2013-12-31 | Amgen Inc | TRPM8 antagonists and their use in treatments |
MX340756B (es) * | 2011-08-04 | 2016-07-25 | Array Biopharma Inc | Compuestos de quinazolina como inhibidores de serina/treonina quinasa. |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
US9624172B2 (en) | 2014-02-17 | 2017-04-18 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
WO2016057572A1 (en) | 2014-10-06 | 2016-04-14 | Mark Thomas Miller | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2016055934A1 (en) * | 2014-10-09 | 2016-04-14 | Glenmark Pharmaceuticals Limited | Amorphous form of lomitapide mesylate |
ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
DK3519401T3 (da) | 2016-09-30 | 2021-11-22 | Vertex Pharma | Modulator af cystisk fibrosetransmembrankonduktansregulator, farmaceutiske sammensætninger, fremgangsmåder til behandling og fremgangsmåde til fremstilling af modulatoren |
JOP20190125B1 (ar) | 2016-12-09 | 2022-03-14 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
EP3640242B1 (en) * | 2017-06-16 | 2023-04-19 | Hitgen Ltd. | Rock-inhibiting compound and uses thereof |
CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018309043B2 (en) | 2017-08-02 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2819039A1 (de) | 1978-04-29 | 1979-11-08 | Bayer Ag | Leimungsmittel fuer papier |
DK104382A (da) | 1981-03-11 | 1982-09-12 | Wellcome Found | Fremgangsmaade til fremstilling af substituerede biphenylforbindelser |
EP0580860B2 (en) | 1991-04-16 | 2004-12-15 | Nippon Shinyaku Company, Limited | Method of manufacturing solid dispersion |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
HU218419B (hu) | 1992-03-06 | 2000-08-28 | E.R. Squibb And Sons, Inc. | Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
RO114445B1 (ro) | 1994-05-27 | 1999-04-30 | Smithkline Beecham S.P.A. | Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament |
DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
DE19519245C2 (de) * | 1995-04-14 | 2003-04-30 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
EP0832069B1 (en) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
MX9709914A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
CZ296163B6 (cs) * | 1996-05-20 | 2006-01-11 | Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV | |
EP1019378B1 (en) | 1996-07-01 | 2004-09-29 | Eli Lilly And Company | Hypoglycemic and hypolipidemic compounds |
KR100217618B1 (ko) * | 1996-12-12 | 1999-09-01 | 정몽규 | 와셔액 분사위치 조절 장치 |
AU5513298A (en) | 1996-12-20 | 1998-07-17 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
AP1201A (en) | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
PL341364A1 (en) * | 1997-12-22 | 2001-04-09 | Upjohn Co | 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents |
CO5090829A1 (es) | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
IL139449A0 (en) | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Use of apo b secretion/mtp inhibitors |
CA2325358C (en) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
US6417367B1 (en) * | 2000-08-11 | 2002-07-09 | Pfizer Inc. | Methods of making quinoline amides |
JP2004510763A (ja) | 2000-10-05 | 2004-04-08 | 藤沢薬品工業株式会社 | アポb分泌阻害剤としてのベンズアミド化合物 |
KR100575944B1 (ko) | 2001-06-28 | 2006-05-02 | 화이자 프로덕츠 인코포레이티드 | 미소체 트리글리세라이드 전달 단백질(mtp) 및/또는아포지방단백질 b(apo b)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜 |
CA2464981A1 (en) * | 2001-10-25 | 2003-05-01 | Takeda Chemical Industries, Ltd. | Quinoline compound |
AU2002360489A1 (en) * | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
US20030162788A1 (en) * | 2002-01-10 | 2003-08-28 | Boehringer Ingelheim Pharma Kg | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals |
CA2460682C (en) | 2002-02-28 | 2010-11-30 | Japan Tobacco Inc. | Ester compound and medical use thereof |
CA2505604A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
EP1581499A1 (en) * | 2002-12-20 | 2005-10-05 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
EA010369B1 (ru) * | 2004-02-04 | 2008-08-29 | Пфайзер Продактс Инк. | Замещенные хинолиновые соединения |
-
2005
- 2005-01-24 EA EA200601239A patent/EA010369B1/ru not_active IP Right Cessation
- 2005-01-24 BR BRPI0507462-2A patent/BRPI0507462A/pt not_active IP Right Cessation
- 2005-01-24 GE GEAP20059563A patent/GEP20084360B/en unknown
- 2005-01-24 JP JP2006551942A patent/JP2007520543A/ja active Pending
- 2005-01-24 EP EP05702327A patent/EP1716137A1/en not_active Withdrawn
- 2005-01-24 AP AP2006003685A patent/AP2006003685A0/xx unknown
- 2005-01-24 OA OA1200600247A patent/OA13365A/en unknown
- 2005-01-24 KR KR1020067015770A patent/KR100799802B1/ko not_active IP Right Cessation
- 2005-01-24 CA CA002555133A patent/CA2555133A1/en not_active Abandoned
- 2005-01-24 AU AU2005214159A patent/AU2005214159A1/en not_active Abandoned
- 2005-01-24 WO PCT/IB2005/000167 patent/WO2005080373A1/en active Application Filing
- 2005-02-02 AR ARP050100394A patent/AR047529A1/es not_active Application Discontinuation
- 2005-02-02 PE PE2005000125A patent/PE20050773A1/es not_active Application Discontinuation
- 2005-02-02 UY UY28734A patent/UY28734A1/es unknown
- 2005-02-03 US US11/049,852 patent/US7468378B2/en not_active Expired - Fee Related
- 2005-02-03 TW TW094103301A patent/TWI306454B/zh not_active IP Right Cessation
- 2005-02-03 TW TW097141214A patent/TW200906800A/zh unknown
- 2005-02-04 PA PA20058623001A patent/PA8623001A1/es unknown
- 2005-02-04 NL NL1028192A patent/NL1028192C2/nl not_active IP Right Cessation
- 2005-02-04 SV SV2005002007A patent/SV2007002007A/es not_active Application Discontinuation
-
2006
- 2006-06-15 US US11/424,488 patent/US7368573B2/en not_active Expired - Fee Related
- 2006-07-05 IL IL176715A patent/IL176715A0/en unknown
- 2006-07-21 EC EC2006006717A patent/ECSP066717A/es unknown
- 2006-07-28 CO CO06074303A patent/CO5700721A2/es not_active Application Discontinuation
- 2006-08-03 CR CR8544A patent/CR8544A/es not_active Application Discontinuation
- 2006-08-04 MA MA29241A patent/MA28347A1/fr unknown
- 2006-09-01 NO NO20063928A patent/NO20063928L/no not_active Application Discontinuation
- 2006-10-30 US US11/554,351 patent/US7393958B2/en not_active Expired - Fee Related
-
2010
- 2010-10-27 IL IL208963A patent/IL208963A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066717A (es) | Compuestos de quinolina sustituidos | |
ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
SV2005001973A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) | |
ECSP067120A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
UY29253A1 (es) | 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento | |
ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
CR9834A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia | |
ECSP078060A (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
ECSP088527A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
ECSP088103A (es) | Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia | |
CR10489A (es) | Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides | |
ECSP066991A (es) | 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
UY29414A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
ECSP066770A (es) | Nuevos ésteres de quinuclidina cuaternizados | |
UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
ECSP056006A (es) | Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas | |
GT200500310A (es) | Compuestos organicos | |
DOP2006000024A (es) | Tiazolidinonas, su preparación y su uso como medicamento | |
UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones | |
UY29308A1 (es) | Derivado de quinolina, su uso, preparación y medicamento que lo contiene |